<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961658</url>
  </required_header>
  <id_info>
    <org_study_id>CT-GEM-001</org_study_id>
    <nct_id>NCT04961658</nct_id>
  </id_info>
  <brief_title>Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients</brief_title>
  <acronym>AMETHYST</acronym>
  <official_title>Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bacterial sepsis occurs in patients with severe infections. The condition is caused by toxic&#xD;
      substances (toxins) released from bacteria and the patient's elevated inflammatory response&#xD;
      to those toxins. In preclinical studies, human mesenchymal stromal cells (MSCs) have been&#xD;
      proven to modulate host inflammation in infections, including sepsis. The purpose of this&#xD;
      Phase I, open label, dose escalation safety trial is to determine whether escalating doses of&#xD;
      enhanced MSCs (GEM00220) are safe and well tolerated in patients with septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>A dose-escalation study evaluating GEM00220 cell therapy in 3 cohorts with 3 subjects per cohort. Study will proceed from lower dose to next higher dose if no safety concerns are observed in each cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of GEM00220 will be assessed by monitoring adverse events</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Feasible Tolerated Dose</measure>
    <time_frame>Baseline to 28 days</time_frame>
    <description>The highest dose which does not meet any of the pre-defined stopping criteria</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Treatment Arm - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of 3 subjects who receive a single dose of GEM00220 at 15 million cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm - Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of 3 subjects who receive a single dose of GEM00220 at 60 million cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of 3 subjects who receive a single dose of GEM00220 at 150 million cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEM00220</intervention_name>
    <description>Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion</description>
    <arm_group_label>Treatment Arm - Low Dose</arm_group_label>
    <arm_group_label>Treatment arm - High dose</arm_group_label>
    <arm_group_label>Treatment arm - Mid dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients age 18 years and older&#xD;
&#xD;
          2. Receipt of appropriate antibiotics for the suspected/confirmed bacterial sepsis as the&#xD;
             main diagnosis according to the opinion of the treating critical care staff physician.&#xD;
&#xD;
          3. Refractory hypotension documented within 48 hours prior to enrolment that requires the&#xD;
             institution and ongoing use of vasopressor agents (phenylephrine, norepinephrine,&#xD;
             vasopressin, epinephrine, or dopamine &gt;5 mcg/kg/min) for at least 3 hours at the time&#xD;
             of enrolment, despite adequate fluid resuscitation in the opinion of the qualified&#xD;
             investigator.&#xD;
&#xD;
          4. At least 1 other new organ dysfunction defined by the following:&#xD;
&#xD;
               1. Renal: Acute kidney injury with creatinine ≥ 150 µmol/L, or ≥ 1.5x the upper&#xD;
                  limit of normal or the known baseline creatinine, or &lt; 0.5 ml/kg/hr urine output&#xD;
                  for 6 hours despite adequate fluid resuscitation (patients on chronic&#xD;
                  hemodialysis or peritoneal dialysis must meet one of the other organ dysfunction&#xD;
                  criteria)&#xD;
&#xD;
               2. Respiratory: Need for invasive mechanical ventilation or a P/F ratio &lt; 250&#xD;
&#xD;
               3. Hematological: Platelets &lt; 100 x10^9/L, or a drop of 50 x10^9/L in the 3 days&#xD;
                  prior to enrollment&#xD;
&#xD;
               4. Metabolic Acidosis: Arterial pH &lt; 7.30 or base deficit &gt; 5 mmol/L in association&#xD;
                  with a lactate &gt;/= to 3.0 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating&#xD;
&#xD;
          2. Currently receiving extracorporeal life support&#xD;
&#xD;
          3. Documented COVID-19 (SARS-CoV2) or influenza infection (confirmed by laboratory&#xD;
             testing)&#xD;
&#xD;
          4. Presence of any active malignancy (other than non-melanoma skin cancer) that required&#xD;
             treatment within the past year&#xD;
&#xD;
          5. History of severe heart failure with a New York Heart Association Functional Class of&#xD;
             III or IV, or severe ischemic heart disease with a Canadian Cardiovascular Society&#xD;
             angina class score of III or IV&#xD;
&#xD;
          6. Moderate to severe chronic liver disease (Childs-Pugh Score &gt; 12)&#xD;
&#xD;
          7. Severe chronic respiratory disease with a baseline PaCO2 &gt; 50 mm Hg or the use of home&#xD;
             oxygen&#xD;
&#xD;
          8. Documented deep venous thrombosis or pulmonary embolism within the past 3 months&#xD;
&#xD;
          9. Chronic immunosuppression (any chronic immunotherapy including daily oral steroid use&#xD;
             &gt;6months)&#xD;
&#xD;
         10. Uncontrolled HIV infection or end stage HIV/AIDS with CD4+ T-cell counts &lt;50&#xD;
             cells/mm^3, history of hepatitis B, untreated hepatitis C, or active tuberculosis&#xD;
&#xD;
         11. Concurrent use of immunomodulatory biologic drugs or TNF-α inhibitors&#xD;
&#xD;
         12. Participation in another interventional study involving an investigational new drug&#xD;
             within 30 days prior to enrolment&#xD;
&#xD;
         13. Moribund patient not expected to survive 24 hours&#xD;
&#xD;
         14. Patient, surrogate, or physician not committed to full support (exception: a patient&#xD;
             will not be excluded if he/she would receive all supportive care except for attempts&#xD;
             at resuscitation from cardiac arrest)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Callahan, MD, DTM&amp;H (UK), MSPH</last_name>
    <phone>343-291-1197</phone>
    <email>mvcallahan@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Bowden, PhD, MSc, CCRP</last_name>
    <phone>343-291-1197</phone>
    <email>kbowden@northernther.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lakeridge Health</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Soliman, MD, FRCP</last_name>
    </contact>
    <investigator>
      <last_name>Karim Soliman, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia dos Santos, MD, MSc, BSc</last_name>
    </contact>
    <investigator>
      <last_name>Claudia dos Santos, MD, MSc, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Marshall, MD, FRCSC, FACS, FCAHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Bacteria</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>Mesenchymal Stromal Cells</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

